George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024
31 août 2024 03h54 HE
|
George Medicines
George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024 Results from two Phase III trials...
MCL1 Inhibitor Drug Clinical Trials & Commercialization Opportunity Insights Analysis 2024: Focus on 10 ML1 Inhibitor Drug In Clinical Trials, Insight By Company, Indication and Phase
26 août 2024 11h02 HE
|
Research and Markets
Dublin, Aug. 26, 2024 (GLOBE NEWSWIRE) -- The "MCL1 Inhibitor Drug Clinical Trials & Commercialization Opportunity Insights 2024" report has been added to ResearchAndMarkets.com's offering. ...
CenExel Announces Ryan Brooks as Executive Chairman & Interim CEO
12 août 2024 09h10 HE
|
CenExel Clinical Research
Salt Lake City, UT, Aug. 12, 2024 (GLOBE NEWSWIRE) -- CenExel, a leading clinical research site network, proudly announces the appointment of Ryan Brooks as Executive Chairman of the Board and...
Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC
06 août 2024 08h00 HE
|
Science 37, Inc.
Science 37 opens new, state-of-the-art facility, to enhance collaboration and improve patient recruitment and study support for clinical trials.
Understanding Pharmacovigilance Regulations in Asia-Pacific: 2-Day Training Course (Online) October 8-9, 2024 - RPPV (QPPV), PSMF, RMP, and Other Related Regulations
05 août 2024 04h24 HE
|
Research and Markets
Dublin, Aug. 05, 2024 (GLOBE NEWSWIRE) -- The "Understanding Pharmacovigilance Regulations in APAC Training Course" conference has been added to ResearchAndMarkets.com's offering. ...
Registration Now Open for the 2025 MDA Clinical & Scientific Conference Featuring the Latest Innovations in Neuromuscular Disease Research and Care with Global Leaders, March 16-19 in Dallas, TX
30 juil. 2024 11h53 HE
|
Muscular Dystrophy Association
New York, July 30, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA), convener of the largest global gathering of the neuromuscular disease community, announced today that...
Science 37 Enrolls 42% of Trial Cohort in 8 Weeks
18 juil. 2024 08h00 HE
|
Science 37, Inc.
Science 37 enrolls 65 patients per month for its sponsor's Phase 3 infectious disease clinical trial.
First patient dosed in Phase 3 Gliofocus Study for newly diagnosed glioblastoma patients at the Ivy Brain Tumor Center
17 juil. 2024 08h00 HE
|
Ivy Brain Tumor Center
Phoenix, AZ, July 17, 2024 (GLOBE NEWSWIRE) -- Gliofocus is a global, registrational, randomized, controlled Phase 3 clinical trial comparing niraparib vs temozolomide in newly diagnosed...
Dementia Mission Competition Selects Four Companies For Innovative Alzheimer’s Biomarker Study
10 juil. 2024 09h05 HE
|
Global Alzheimer’s Platform Foundation®
Washington D.C., July 10, 2024 (GLOBE NEWSWIRE) -- With groundbreaking creativity and breathtaking speed, this phase 3 competition, funded by Innovate UK, the UK’s innovation agency, is supporting...
Scientific Presentations Highlight OGM’s Utility for Cancer Research at Joint Annual Meeting for Three Molecular and Cytogenetic Associations
02 juil. 2024 08h00 HE
|
Bionano Laboratories
At a sponsored workshop, Su Yang from The University of Texas MD Anderson Cancer Center will present case studies that demonstrate the ability of the optical genome mapping (OGM) workflow to detect...